Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Glioblastoma Multiforme (GBM) – Pipeline Review, H2 2017’, provides an overview of the Glioblastoma Multiforme (GBM) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glioblastoma Multiforme (GBM), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glioblastoma Multiforme (GBM) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Glioblastoma Multiforme (GBM)

The report reviews pipeline therapeutics for Glioblastoma Multiforme (GBM) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Glioblastoma Multiforme (GBM) therapeutics and enlists all their major and minor projects

The report assesses Glioblastoma Multiforme (GBM) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Glioblastoma Multiforme (GBM)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Glioblastoma Multiforme (GBM)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Glioblastoma Multiforme (GBM) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AbbVie Inc

Accurexa Inc

Actuate Therapeutics Inc

Aduro BioTech Inc

Advantagene Inc

Advenchen Laboratories LLC

Affimed GmbH

Agenus Inc

Ambrx Inc

Amgen Inc

Ampio Pharmaceuticals Inc

AngioChem Inc

Apac Biotech Pvt Ltd

apceth Biopharma GmbH

APIM Therapeutics AS

Apogenix AG

Ariad Pharmaceuticals Inc

Arog Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Athenex Inc

Basilea Pharmaceutica Ltd

Batu Biologics Inc

Bayer AG

Beactica AB

BeiGene Ltd

Berg LLC

Bexion Pharmaceuticals LLC

BeyondSpring Pharmaceuticals Inc

Bio-Path Holdings Inc

Bioasis Technologies Inc

BioCancell Ltd

Biovista Inc

Boehringer Ingelheim GmbH

Boston Biomedical Inc

Bristol-Myers Squibb Co

Cantex Pharmaceuticals Inc

Cavion LLC

Celgene Corp

Celldex Therapeutics Inc

Cellmid Ltd

Celsion Corp

ChemoCentryx Inc

Coherus BioSciences Inc

Cortice Biosciences Inc

Critical Outcome Technologies Inc

Curtana Pharmaceuticals Inc

Cynata Therapeutics Ltd

CytoVac AS

Daiichi Sankyo Co Ltd

Deciphera Pharmaceuticals LLC

DEKK-TEC Inc

DelMar Pharmaceuticals Inc

Diffusion Pharmaceuticals Inc

Dr. Reddy's Laboratories Ltd

Ecrins Therapeutics SAS

Eisai Co Ltd

Eli Lilly and Co

EnGeneIC Ltd

Enterome Bioscience SA

EntreChem SL

ERC Belgium SA

Erytech Pharma SA

Evotec AG

F-star Biotechnology Ltd

F. Hoffmann-La Roche Ltd

FirstString Research Inc

Fujifilm Holdings Corporation

Gene Techno Science Co Ltd

Genentech Inc

Genisphere LLC

Genor BioPharma Co Ltd

GlaxoSmithKline Plc

GlioPharma ApS

GtreeBNT Co Ltd

GW Pharmaceuticals Plc

Hamlet Pharma AB

Hanmi Pharmaceuticals Co Ltd

Humanigen Inc

Hutchison MediPharma Ltd

Immatics Biotechnologies GmbH

Immune Pharmaceuticals Inc

ImmunoCellular Therapeutics Ltd

Immunomedics Inc

Immunomet Therapeutics Inc

Immunomic Therapeutics Inc

Incyte Corp

Infinity Pharmaceuticals Inc

Innovation Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Inspyr Therapeutics Inc

Insys Therapeutics Inc

Iovance Biotherapeutics Inc

Ipsen SA

Janpix Inc

Jiangsu Kanion Pharmaceutical Co Ltd

Johnson & Johnson

Juno Therapeutics Inc

Kadmon Corp LLC

Karyopharm Therapeutics Inc

Kazia Therapeutics Ltd

Kite Pharma Inc

Komipharm International Co Ltd

Kringle Pharma Inc

Kyorin Pharmaceutical Co Ltd

Les Laboratoires Servier SAS

Lixte Biotechnology Holdings Inc

Loxo Oncology Inc

Mabion SA

MacroGenics Inc

Medesis Pharma SA

Medicenna Therapeutics Corp

MedImmune LLC

Merck & Co Inc

Merck KGaA

Midatech Pharma Plc

Millennium Pharmaceuticals Inc

MimiVax LLC

Molecular Templates Inc

Moleculin Biotech Inc

Mycenax Biotech Inc

NanoCarrier Co Ltd

Nanomerics Ltd

Nektar Therapeutics

Neonc Technologies Inc

NewLink Genetics Corp

Northwest Biotherapeutics Inc

Novartis AG

Noxopharm Ltd

Noxxon Pharma AG

Nuo Therapeutics Inc

NuvOx Pharma LLC

Omniox Inc

Oncobiologics Inc

Oncodesign SA

Onconova Therapeutics Inc

OncoResponse Inc

Oncternal Therapeutics Inc

Ono Pharmaceutical Co Ltd

Orphit SAS

Oryx GmbH & Co KG

Ovensa Inc

Peloton Therapeutics Inc

Peptomyc SL

Peregrine Pharmaceuticals Inc

Pfizer Inc

Pharma Mar SA

PharmAbcine Inc

PharmaCyte Biotech Inc

Pharmicell Co Ltd

Phoenix Biotechnology Inc

PIQUR Therapeutics AG

Plex Pharmaceuticals Inc

Plexxikon Inc

Prana Biotechnology Ltd

PTC Therapeutics Inc

Puma Biotechnology Inc

Regulus Therapeutics Inc

ReNeuron Group Plc

Rgenix Inc

Richter Gedeon Nyrt

Sanofi

Sapience Therapeutics Inc

Scancell Holdings Plc

Sellas Life Sciences Group Ltd

Sigma-Tau SpA

SignPath Pharma Inc

Silenseed Ltd

SOM Biotech SL

Sorrento Therapeutics Inc

StemGen SpA

Stemline Therapeutics Inc

Sumitomo Dainippon Pharma Co Ltd

Sun Pharma Advanced Research Company Ltd

Sunesis Pharmaceuticals Inc

Susavion Biosciences Inc

Symphogen A/S

Synactix Pharmaceuticals Inc

Systimmune Inc

Terpenoid Therapeutics Inc

Theralase Technologies Inc

Therapeia GmbH & Co KG

Tocagen Inc

TRACON Pharmaceuticals Inc

Transgene SA

Trillium Therapeutics Inc

TVAX Biomedical Inc

Tyme Technologies Inc

Upsher-Smith Laboratories Inc

Vascular Biogenics Ltd

Vault Pharma Inc

Vaximm AG

VBI Vaccines Inc

VCN Biosciences SL

ViraTherapeutics GmbH

Vyriad Inc

X4 Pharmaceuticals Inc

Xintela AB

Yooyoung Pharm Co Ltd

ZIOPHARM Oncology Inc

Table of Contents

Table of Contents

Table of Contents 2

Introduction 9

Glioblastoma Multiforme (GBM) - Overview 10

Glioblastoma Multiforme (GBM) - Therapeutics Development 11

Glioblastoma Multiforme (GBM) - Therapeutics Assessment 59

Glioblastoma Multiforme (GBM) - Companies Involved in Therapeutics Development 86

Glioblastoma Multiforme (GBM) - Drug Profiles 174

Glioblastoma Multiforme (GBM) - Dormant Projects 1503

Glioblastoma Multiforme (GBM) - Discontinued Products 1515

Glioblastoma Multiforme (GBM) - Product Development Milestones 1517

Appendix 1531

List of Tables

List of Tables

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017 54

Number of Products under Development by Companies, H2 2017 56

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 57

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017 58

Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017 59

Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017 60

Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017 61

Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017 62

Number of Products under Development by Companies, H2 2017 (Contd..7), H2 2017 63

Number of Products under Development by Companies, H2 2017 (Contd..8), H2 2017 64

Number of Products under Development by Companies, H2 2017 (Contd..9), H2 2017 65

Number of Products under Development by Companies, H2 2017 (Contd..10), H2 2017 66

Number of Products under Development by Companies, H2 2017 (Contd..11), H2 2017 67

Number of Products under Development by Companies, H2 2017 (Contd..12), H2 2017 68

Number of Products under Development by Companies, H2 2017 (Contd..13), H2 2017 69

Number of Products under Development by Companies, H2 2017 (Contd..14), H2 2017 70

Number of Products under Development by Universities/Institutes, H2 2017 71

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 73

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 74

Number of Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 75

Products under Development by Companies, H2 2017 76

Products under Development by Companies, H2 2017 (Contd..1), H2 2017 77

Products under Development by Companies, H2 2017 (Contd..2), H2 2017 78

Products under Development by Companies, H2 2017 (Contd..3), H2 2017 79

Products under Development by Companies, H2 2017 (Contd..4), H2 2017 80

Products under Development by Companies, H2 2017 (Contd..5), H2 2017 81

Products under Development by Companies, H2 2017 (Contd..6), H2 2017 82

Products under Development by Companies, H2 2017 (Contd..7), H2 2017 83

Products under Development by Companies, H2 2017 (Contd..8), H2 2017 84

Products under Development by Companies, H2 2017 (Contd..9), H2 2017 85

Products under Development by Companies, H2 2017 (Contd..10), H2 2017 86

Products under Development by Companies, H2 2017 (Contd..11), H2 2017 87

Products under Development by Companies, H2 2017 (Contd..12), H2 2017 88

Products under Development by Companies, H2 2017 (Contd..13), H2 2017 89

Products under Development by Companies, H2 2017 (Contd..14), H2 2017 90

Products under Development by Companies, H2 2017 (Contd..15), H2 2017 91

Products under Development by Companies, H2 2017 (Contd..16), H2 2017 92

Products under Development by Companies, H2 2017 (Contd..17), H2 2017 93

Products under Development by Companies, H2 2017 (Contd..18), H2 2017 94

Products under Development by Companies, H2 2017 (Contd..19), H2 2017 95

Products under Development by Companies, H2 2017 (Contd..20), H2 2017 96

Products under Development by Universities/Institutes, H2 2017 97

Products under Development by Universities/Institutes, H2 2017 (Contd..1), H2 2017 98

Products under Development by Universities/Institutes, H2 2017 (Contd..2), H2 2017 100

Products under Development by Universities/Institutes, H2 2017 (Contd..3), H2 2017 101

Number of Products by Stage and Target, H2 2017 103

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 104

Number of Products by Stage and Target, H2 2017 (Contd..2), H2 2017 105

Number of Products by Stage and Target, H2 2017 (Contd..3), H2 2017 106

Number of Products by Stage and Target, H2 2017 (Contd..4), H2 2017 107

Number of Products by Stage and Target, H2 2017 (Contd..5), H2 2017 108

Number of Products by Stage and Target, H2 2017 (Contd..6), H2 2017 109

Number of Products by Stage and Target, H2 2017 (Contd..7), H2 2017 110

Number of Products by Stage and Target, H2 2017 (Contd..8), H2 2017 111

Number of Products by Stage and Target, H2 2017 (Contd..9), H2 2017 112

Number of Products by Stage and Mechanism of Action, H2 2017 114

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 115

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2 2017 116

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2 2017 117

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2 2017 118

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..5), H2 2017 119

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..6), H2 2017 120

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..7), H2 2017 121

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..8), H2 2017 122

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..9), H2 2017 123

Number of Products by Stage and Route of Administration, H2 2017 125

Number of Products by Stage and Molecule Type, H2 2017 127

Number of Products by Stage and Molecule Type, H2 2017 (Contd..1), H2 2017 128

Glioblastoma Multiforme (GBM) – Pipeline by AbbVie Inc, H2 2017 129

Glioblastoma Multiforme (GBM) – Pipeline by Accurexa Inc, H2 2017 130

Glioblastoma Multiforme (GBM) – Pipeline by Actuate Therapeutics Inc, H2 2017 130

Glioblastoma Multiforme (GBM) – Pipeline by Aduro BioTech Inc, H2 2017 130

Glioblastoma Multiforme (GBM) – Pipeline by Advantagene Inc, H2 2017 131

Glioblastoma Multiforme (GBM) – Pipeline by Advenchen Laboratories LLC, H2 2017 131

Glioblastoma Multiforme (GBM) – Pipeline by Affimed GmbH, H2 2017 132

Glioblastoma Multiforme (GBM) – Pipeline by Agenus Inc, H2 2017 132

Glioblastoma Multiforme (GBM) – Pipeline by Ambrx Inc, H2 2017 133

Glioblastoma Multiforme (GBM) – Pipeline by Amgen Inc, H2 2017 133

Glioblastoma Multiforme (GBM) – Pipeline by Ampio Pharmaceuticals Inc, H2 2017 134

Glioblastoma Multiforme (GBM) – Pipeline by AngioChem Inc, H2 2017 134

Glioblastoma Multiforme (GBM) – Pipeline by Apac Biotech Pvt Ltd, H2 2017 134

Glioblastoma Multiforme (GBM) – Pipeline by apceth Biopharma GmbH, H2 2017 135

Glioblastoma Multiforme (GBM) – Pipeline by APIM Therapeutics AS, H2 2017 135

Glioblastoma Multiforme (GBM) – Pipeline by Apogenix AG, H2 2017 135

Glioblastoma Multiforme (GBM) – Pipeline by Ariad Pharmaceuticals Inc, H2 2017 136

Glioblastoma Multiforme (GBM) – Pipeline by Arog Pharmaceuticals Inc, H2 2017 136

Glioblastoma Multiforme (GBM) – Pipeline by Astellas Pharma Inc, H2 2017 137

Glioblastoma Multiforme (GBM) – Pipeline by AstraZeneca Plc, H2 2017 137

Glioblastoma Multiforme (GBM) – Pipeline by Athenex Inc, H2 2017 138

Glioblastoma Multiforme (GBM) – Pipeline by Basilea Pharmaceutica Ltd, H2 2017 138

Glioblastoma Multiforme (GBM) – Pipeline by Batu Biologics Inc, H2 2017 138

Glioblastoma Multiforme (GBM) – Pipeline by Bayer AG, H2 2017 139

Glioblastoma Multiforme (GBM) – Pipeline by Beactica AB, H2 2017 139

Glioblastoma Multiforme (GBM) – Pipeline by BeiGene Ltd, H2 2017 140

Glioblastoma Multiforme (GBM) – Pipeline by Berg LLC, H2 2017 140

Glioblastoma Multiforme (GBM) – Pipeline by Bexion Pharmaceuticals LLC, H2 2017 141

Glioblastoma Multiforme (GBM) – Pipeline by BeyondSpring Pharmaceuticals Inc, H2 2017 141

Glioblastoma Multiforme (GBM) – Pipeline by Bio-Path Holdings Inc, H2 2017 142

Glioblastoma Multiforme (GBM) – Pipeline by Bioasis Technologies Inc, H2 2017 142

Glioblastoma Multiforme (GBM) – Pipeline by BioCancell Ltd, H2 2017 142

Glioblastoma Multiforme (GBM) – Pipeline by Biovista Inc, H2 2017 143

Glioblastoma Multiforme (GBM) – Pipeline by Boehringer Ingelheim GmbH, H2 2017 143

Glioblastoma Multiforme (GBM) – Pipeline by Boston Biomedical Inc, H2 2017 144

Glioblastoma Multiforme (GBM) – Pipeline by Bristol-Myers Squibb Co, H2 2017 144

Glioblastoma Multiforme (GBM) – Pipeline by Cantex Pharmaceuticals Inc, H2 2017 145

Glioblastoma Multiforme (GBM) – Pipeline by Cavion LLC, H2 2017 145

Glioblastoma Multiforme (GBM) – Pipeline by Celgene Corp, H2 2017 146

Glioblastoma Multiforme (GBM) – Pipeline by Celldex Therapeutics Inc, H2 2017 146

Glioblastoma Multiforme (GBM) – Pipeline by Cellmid Ltd, H2 2017 147

Glioblastoma Multiforme (GBM) – Pipeline by Celsion Corp, H2 2017 147

Glioblastoma Multiforme (GBM) – Pipeline by ChemoCentryx Inc, H2 2017 148

Glioblastoma Multiforme (GBM) – Pipeline by Coherus BioSciences Inc, H2 2017 148

Glioblastoma Multiforme (GBM) – Pipeline by Cortice Biosciences Inc, H2 2017 149

Glioblastoma Multiforme (GBM) – Pipeline by Critical Outcome Technologies Inc, H2 2017 149

Glioblastoma Multiforme (GBM) – Pipeline by Curtana Pharmaceuticals Inc, H2 2017 149

Glioblastoma Multiforme (GBM) – Pipeline by Cynata Therapeutics Ltd, H2 2017 150

Glioblastoma Multiforme (GBM) – Pipeline by CytoVac AS, H2 2017 150

Glioblastoma Multiforme (GBM) – Pipeline by Daiichi Sankyo Co Ltd, H2 2017 151

Glioblastoma Multiforme (GBM) – Pipeline by Deciphera Pharmaceuticals LLC, H2 2017 151

Glioblastoma Multiforme (GBM) – Pipeline by DEKK-TEC Inc, H2 2017 151

Glioblastoma Multiforme (GBM) – Pipeline by DelMar Pharmaceuticals Inc, H2 2017 152

Glioblastoma Multiforme (GBM) – Pipeline by Diffusion Pharmaceuticals Inc, H2 2017 152

Glioblastoma Multiforme (GBM) – Pipeline by Dr. Reddy's Laboratories Ltd, H2 2017 153

Glioblastoma Multiforme (GBM) – Pipeline by Ecrins Therapeutics SAS, H2 2017 153

Glioblastoma Multiforme (GBM) – Pipeline by Eisai Co Ltd, H2 2017 154

Glioblastoma Multiforme (GBM) – Pipeline by Eli Lilly and Co, H2 2017 154

Glioblastoma Multiforme (GBM) – Pipeline by EnGeneIC Ltd, H2 2017 155

Glioblastoma Multiforme (GBM) – Pipeline by Enterome Bioscience SA, H2 2017 155

Glioblastoma Multiforme (GBM) – Pipeline by EntreChem SL, H2 2017 155

Glioblastoma Multiforme (GBM) – Pipeline by ERC Belgium SA, H2 2017 156

Glioblastoma Multiforme (GBM) – Pipeline by Erytech Pharma SA, H2 2017 156

Glioblastoma Multiforme (GBM) – Pipeline by Evotec AG, H2 2017 157

Glioblastoma Multiforme (GBM) – Pipeline by F-star Biotechnology Ltd, H2 2017 157

Glioblastoma Multiforme (GBM) – Pipeline by F. Hoffmann-La Roche Ltd, H2 2017 158

Glioblastoma Multiforme (GBM) – Pipeline by FirstString Research Inc, H2 2017 158

Glioblastoma Multiforme (GBM) – Pipeline by Fujifilm Holdings Corporation, H2 2017 159

Glioblastoma Multiforme (GBM) – Pipeline by Gene Techno Science Co Ltd, H2 2017 159

Glioblastoma Multiforme (GBM) – Pipeline by Genentech Inc, H2 2017 160

Glioblastoma Multiforme (GBM) – Pipeline by Genisphere LLC, H2 2017 160

Glioblastoma Multiforme (GBM) – Pipeline by Genor BioPharma Co Ltd, H2 2017 160

Glioblastoma Multiforme (GBM) – Pipeline by GlaxoSmithKline Plc, H2 2017 161

Glioblastoma Multiforme (GBM) – Pipeline by GlioPharma ApS, H2 2017 161

Glioblastoma Multiforme (GBM) – Pipeline by GtreeBNT Co Ltd, H2 2017 162

Glioblastoma Multiforme (GBM) – Pipeline by GW Pharmaceuticals Plc, H2 2017 162

Glioblastoma Multiforme (GBM) – Pipeline by Hamlet Pharma AB, H2 2017 162

Glioblastoma Multiforme (GBM) – Pipeline by Hanmi Pharmaceuticals Co Ltd, H2 2017 163

Glioblastoma Multiforme (GBM) – Pipeline by Humanigen Inc, H2 2017 163

Glioblastoma Multiforme (GBM) – Pipeline by Hutchison MediPharma Ltd, H2 2017 164

Glioblastoma Multiforme (GBM) – Pipeline by Immatics Biotechnologies GmbH, H2 2017 164

Glioblastoma Multiforme (GBM) – Pipeline by Immune Pharmaceuticals Inc, H2 2017 165

Glioblastoma Multiforme (GBM) – Pipeline by ImmunoCellular Therapeutics Ltd, H2 2017 165

Glioblastoma Multiforme (GBM) – Pipeline by Immunomedics Inc, H2 2017 166

Glioblastoma Multiforme (GBM) – Pipeline by Immunomet Therapeutics Inc, H2 2017 166

Glioblastoma Multiforme (GBM) – Pipeline by Immunomic Therapeutics Inc, H2 2017 166

Glioblastoma Multiforme (GBM) – Pipeline by Incyte Corp, H2 2017 167

Glioblastoma Multiforme (GBM) – Pipeline by Infinity Pharmaceuticals Inc, H2 2017 167

Glioblastoma Multiforme (GBM) – Pipeline by Innovation Pharmaceuticals Inc, H2 2017 168

Glioblastoma Multiforme (GBM) – Pipeline by Inovio Pharmaceuticals Inc, H2 2017 168

Glioblastoma Multiforme (GBM) – Pipeline by Inspyr Therapeutics Inc, H2 2017 169

Glioblastoma Multiforme (GBM) – Pipeline by Insys Therapeutics Inc, H2 2017 169

Glioblastoma Multiforme (GBM) – Pipeline by Iovance Biotherapeutics Inc, H2 2017 170

Glioblastoma Multiforme (GBM) – Pipeline by Ipsen SA, H2 2017 170

Glioblastoma Multiforme (GBM) – Pipeline by Janpix Inc, H2 2017 171

Glioblastoma Multiforme (GBM) – Pipeline by Jiangsu Kanion Pharmaceutical Co Ltd, H2 2017 171

Glioblastoma Multiforme (GBM) – Pipeline by Johnson & Johnson, H2 2017 172

Glioblastoma Multiforme (GBM) – Pipeline by Juno Therapeutics Inc, H2 2017 172

Glioblastoma Multiforme (GBM) – Pipeline by Kadmon Corp LLC, H2 2017 172

Glioblastoma Multiforme (GBM) – Pipeline by Karyopharm Therapeutics Inc, H2 2017 173

Glioblastoma Multiforme (GBM) – Pipeline by Kazia Therapeutics Ltd, H2 2017 173

Glioblastoma Multiforme (GBM) – Pipeline by Kite Pharma Inc, H2 2017 174

Glioblastoma Multiforme (GBM) – Pipeline by Komipharm International Co Ltd, H2 2017 174

Glioblastoma Multiforme (GBM) – Pipeline by Kringle Pharma Inc, H2 2017 175

Glioblastoma Multiforme (GBM) – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017 175

Glioblastoma Multiforme (GBM) – Pipeline by Les Laboratoires Servier SAS, H2 2017 176

Glioblastoma Multiforme (GBM) – Pipeline by Lixte Biotechnology Holdings Inc, H2 2017 176

Glioblastoma Multiforme (GBM) – Pipeline by Loxo Oncology Inc, H2 2017 176

Glioblastoma Multiforme (GBM) – Pipeline by Mabion SA, H2 2017 177

Glioblastoma Multiforme (GBM) – Pipeline by MacroGenics Inc, H2 2017 177

Glioblastoma Multiforme (GBM) – Pipeline by Medesis Pharma SA, H2 2017 178

Glioblastoma Multiforme (GBM) – Pipeline by Medicenna Therapeutics Corp, H2 2017 178

Glioblastoma Multiforme (GBM) – Pipeline by MedImmune LLC, H2 2017 179

Glioblastoma Multiforme (GBM) – Pipeline by Merck & Co Inc, H2 2017 179

Glioblastoma Multiforme (GBM) – Pipeline by Merck KGaA, H2 2017 180

Glioblastoma Multiforme (GBM) – Pipeline by Midatech Pharma Plc, H2 2017 180

Glioblastoma Multiforme (GBM) – Pipeline by Millennium Pharmaceuticals Inc, H2 2017 181

Glioblastoma Multiforme (GBM) – Pipeline by MimiVax LLC, H2 2017 181

Glioblastoma Multiforme (GBM) – Pipeline by Molecular Templates Inc, H2 2017 181

Glioblastoma Multiforme (GBM) – Pipeline by Moleculin Biotech Inc, H2 2017 182

Glioblastoma Multiforme (GBM) – Pipeline by Mycenax Biotech Inc, H2 2017 182

Glioblastoma Multiforme (GBM) – Pipeline by NanoCarrier Co Ltd, H2 2017 183

Glioblastoma Multiforme (GBM) – Pipeline by Nanomerics Ltd, H2 2017 183

Glioblastoma Multiforme (GBM) – Pipeline by Nektar Therapeutics, H2 2017 184

Glioblastoma Multiforme (GBM) – Pipeline by Neonc Technologies Inc, H2 2017 184

Glioblastoma Multiforme (GBM) – Pipeline by NewLink Genetics Corp, H2 2017 185

Glioblastoma Multiforme (GBM) – Pipeline by Northwest Biotherapeutics Inc, H2 2017 185

Glioblastoma Multiforme (GBM) – Pipeline by Novartis AG, H2 2017 186

Glioblastoma Multiforme (GBM) – Pipeline by Noxopharm Ltd, H2 2017 186

Glioblastoma Multiforme (GBM) – Pipeline by Noxxon Pharma AG, H2 2017 186

Glioblastoma Multiforme (GBM) – Pipeline by Nuo Therapeutics Inc, H2 2017 187

Glioblastoma Multiforme (GBM) – Pipeline by NuvOx Pharma LLC, H2 2017 187

Glioblastoma Multiforme (GBM) – Pipeline by Omniox Inc, H2 2017 188

Glioblastoma Multiforme (GBM) – Pipeline by Oncobiologics Inc, H2 2017 188

Glioblastoma Multiforme (GBM) – Pipeline by Oncodesign SA, H2 2017 189

Glioblastoma Multiforme (GBM) – Pipeline by Onconova Therapeutics Inc, H2 2017 189

Glioblastoma Multiforme (GBM) – Pipeline by OncoResponse Inc, H2 2017 189

Glioblastoma Multiforme (GBM) – Pipeline by Oncternal Therapeutics Inc, H2 2017 190

Glioblastoma Multiforme (GBM) – Pipeline by Ono Pharmaceutical Co Ltd, H2 2017 190

Glioblastoma Multiforme (GBM) – Pipeline by Orphit SAS, H2 2017 191

Glioblastoma Multiforme (GBM) – Pipeline by Oryx GmbH & Co KG, H2 2017 191

Glioblastoma Multiforme (GBM) – Pipeline by Ovensa Inc, H2 2017 191

Glioblastoma Multiforme (GBM) – Pipeline by Peloton Therapeutics Inc, H2 2017 192

Glioblastoma Multiforme (GBM) – Pipeline by Peptomyc SL, H2 2017 192

Glioblastoma Multiforme (GBM) – Pipeline by Peregrine Pharmaceuticals Inc, H2 2017 193

Glioblastoma Multiforme (GBM) – Pipeline by Pfizer Inc, H2 2017 193

Glioblastoma Multiforme (GBM) – Pipeline by Pharma Mar SA, H2 2017 194

Glioblastoma Multiforme (GBM) – Pipeline by PharmAbcine Inc, H2 2017 194

Glioblastoma Multiforme (GBM) – Pipeline by PharmaCyte Biotech Inc, H2 2017 195

Glioblastoma Multiforme (GBM) – Pipeline by Pharmicell Co Ltd, H2 2017 195

Glioblastoma Multiforme (GBM) – Pipeline by Phoenix Biotechnology Inc, H2 2017 196

Glioblastoma Multiforme (GBM) – Pipeline by PIQUR Therapeutics AG, H2 2017 196

Glioblastoma Multiforme (GBM) – Pipeline by Plex Pharmaceuticals Inc, H2 2017 196

Glioblastoma Multiforme (GBM) – Pipeline by Plexxikon Inc, H2 2017 197

Glioblastoma Multiforme (GBM) – Pipeline by Prana Biotechnology Ltd, H2 2017 197

Glioblastoma Multiforme (GBM) – Pipeline by PTC Therapeutics Inc, H2 2017 198

Glioblastoma Multiforme (GBM) – Pipeline by Puma Biotechnology Inc, H2 2017 198

Glioblastoma Multiforme (GBM) – Pipeline by Regulus Therapeutics Inc, H2 2017 199

Glioblastoma Multiforme (GBM) – Pipeline by ReNeuron Group Plc, H2 2017 199

Glioblastoma Multiforme (GBM) – Pipeline by Rgenix Inc, H2 2017 199

Glioblastoma Multiforme (GBM) – Pipeline by Richter Gedeon Nyrt, H2 2017 200

Glioblastoma Multiforme (GBM) – Pipeline by Sanofi, H2 2017 200

Glioblastoma Multiforme (GBM) – Pipeline by Sapience Therapeutics Inc, H2 2017 201

Glioblastoma Multiforme (GBM) – Pipeline by Scancell Holdings Plc, H2 2017 201

Glioblastoma Multiforme (GBM) – Pipeline by Sellas Life Sciences Group Ltd, H2 2017 202

Glioblastoma Multiforme (GBM) – Pipeline by Sigma-Tau SpA, H2 2017 202

Glioblastoma Multiforme (GBM) – Pipeline by SignPath Pharma Inc, H2 2017 202

Glioblastoma Multiforme (GBM) – Pipeline by Silenseed Ltd, H2 2017 203

Glioblastoma Multiforme (GBM) – Pipeline by SOM Biotech SL, H2 2017 203

Glioblastoma Multiforme (GBM) – Pipeline by Sorrento Therapeutics Inc, H2 2017 204

Glioblastoma Multiforme (GBM) – Pipeline by StemGen SpA, H2 2017 204

Glioblastoma Multiforme (GBM) – Pipeline by Stemline Therapeutics Inc, H2 2017 205

Glioblastoma Multiforme (GBM) – Pipeline by Sumitomo Dainippon Pharma Co Ltd, H2 2017 205

Glioblastoma Multiforme (GBM) – Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2017 206

Glioblastoma Multiforme (GBM) – Pipeline by Sunesis Pharmaceuticals Inc, H2 2017 206

Glioblastoma Multiforme (GBM) – Pipeline by Susavion Biosciences Inc, H2 2017 207

Glioblastoma Multiforme (GBM) – Pipeline by Symphogen A/S, H2 2017 207

Glioblastoma Multiforme (GBM) – Pipeline by Synactix Pharmaceuticals Inc, H2 2017 207

Glioblastoma Multiforme (GBM) – Pipeline by Systimmune Inc, H2 2017 208

Glioblastoma Multiforme (GBM) – Pipeline by Terpenoid Therapeutics Inc, H2 2017 208

Glioblastoma Multiforme (GBM) – Pipeline by Theralase Technologies Inc, H2 2017 209

Glioblastoma Multiforme (GBM) – Pipeline by Therapeia GmbH & Co KG, H2 2017 209

Glioblastoma Multiforme (GBM) – Pipeline by Tocagen Inc, H2 2017 209

Glioblastoma Multiforme (GBM) – Pipeline by TRACON Pharmaceuticals Inc, H2 2017 210

Glioblastoma Multiforme (GBM) – Pipeline by Transgene SA, H2 2017 210

Glioblastoma Multiforme (GBM) – Pipeline by Trillium Therapeutics Inc, H2 2017 211

Glioblastoma Multiforme (GBM) – Pipeline by TVAX Biomedical Inc, H2 2017 211

Glioblastoma Multiforme (GBM) – Pipeline by Tyme Technologies Inc, H2 2017 211

Glioblastoma Multiforme (GBM) – Pipeline by Upsher-Smith Laboratories Inc, H2 2017 212

Glioblastoma Multiforme (GBM) – Pipeline by Vascular Biogenics Ltd, H2 2017 212

Glioblastoma Multiforme (GBM) – Pipeline by Vault Pharma Inc, H2 2017 213

Glioblastoma Multiforme (GBM) – Pipeline by Vaximm AG, H2 2017 213

Glioblastoma Multiforme (GBM) – Pipeline by VBI Vaccines Inc, H2 2017 213

Glioblastoma Multiforme (GBM) – Pipeline by VCN Biosciences SL, H2 2017 214

Glioblastoma Multiforme (GBM) – Pipeline by ViraTherapeutics GmbH, H2 2017 214

Glioblastoma Multiforme (GBM) – Pipeline by Vyriad Inc, H2 2017 215

Glioblastoma Multiforme (GBM) – Pipeline by X4 Pharmaceuticals Inc, H2 2017 215

Glioblastoma Multiforme (GBM) – Pipeline by Xintela AB, H2 2017 215

Glioblastoma Multiforme (GBM) – Pipeline by Yooyoung Pharm Co Ltd, H2 2017 216

Glioblastoma Multiforme (GBM) – Pipeline by ZIOPHARM Oncology Inc, H2 2017 216

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 1546

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..1), H2 2017 1547

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..2), H2 2017 1548

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..3), H2 2017 1549

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..4), H2 2017 1550

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..5), H2 2017 1551

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..6), H2 2017 1552

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..7), H2 2017 1553

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..8), H2 2017 1554

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..9), H2 2017 1555

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..10), H2 2017 1556

Glioblastoma Multiforme (GBM) – Dormant Projects, H2 2017 (Contd..11), H2 2017 1557

Glioblastoma Multiforme (GBM) – Discontinued Products, H2 2017 1558

Glioblastoma Multiforme (GBM) – Discontinued Products, H2 2017 (Contd..1), H2 2017 1559

List of Figures

List of Figures

Number of Products under Development for Glioblastoma Multiforme (GBM), H2 2017 54

Number of Products under Development by Companies, H2 2017 55

Number of Products under Development by Universities/Institutes, H2 2017 71

Number of Products by Top 10 Targets, H2 2017 102

Number of Products by Stage and Top 10 Targets, H2 2017 102

Number of Products by Top 10 Mechanism of Actions, H2 2017 113

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017 113

Number of Products by Top 10 Routes of Administration, H2 2017 124

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 124

Number of Products by Top 10 Molecule Types, H2 2017 126

Number of Products by Stage and Top 10 Molecule Types, H2 2017 126

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports